Cardiometabolic therapies

Cardiometabolic therapies has been studied in 2 papers since 2026: none in people yet, 2 reviews; 2 in the past year. No study of it in people or animals has been published yet. The newest paper, Oct 2, 2026: “PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction”.

Intervention

2 papers study it2 findingsUpdated

1 new paper in 30 daysSee all 2 papers on cardiometabolic therapies

At a glance

The findings reach people, from one lab or study. 1 lab in 3 countries.

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 3 countries

What did studies of cardiometabolic therapies find?

2

Studies of cardiometabolic therapies measured 2 outcomes: exercise capacity and heart failure outcomes.

Exercise capacity

upin humans1

1 study
  1. Cardiometabolic therapies improve exercise capacity in humans.

    Review

Heart failure outcomes

upin humans1

1 study
  1. Cardiometabolic therapies improve heart failure outcomes in humans.

    Review

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 1Sep 2026: 0Oct 2026: 1Nov 2026: 02 papers in 12 months